Luana Cristina Camargo

Ms. Luana Cristina Camargo

Heinrich Heine University (HHU) Düsseldorf
+1
orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2025 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
PAPatrícia Alencar Alves
Patrícia Alencar Alves
LCLuana Cristina Camargo
Luana Cristina Camargo
GSGabriel Mendonça de Souza
Gabriel Mendonça de Souza
Márcia MortariMárcia Mortari
Márcia Mortari
Mauricio Homem-de-MelloMauricio Homem-de-Mello
Mauricio Homem-de-Mello
The discovery and development of new pharmaceutical drugs is a costly, time-consuming, and highly manual process, with significant challenges in ensuring drug bioavailability at target sites. Computational techniques are highly employed in drug design, particularly to predict the pharmacokinetic properties of molecules. One major kinetic challenge in central nervous system drug development is the permeation through the blood–brain barrier (BBB). Several different computational techniques are used to evaluate both BBB permeability and target delivery. Methods such as quantitative structure–activity relationships, machine learning models, molecular dynamics simulations, end-point free energy calculations, or transporter models have pros and cons for drug development, all contributing to a better understanding of a specific characteristic. Additionally, the design (assisted or not by computers) of prodrug and nanoparticle-based drug delivery systems can enhance BBB permeability by leveraging enzymatic activation and transporter-mediated uptake. Neuroactive peptide computational development is also a relevant field in drug design, since biopharmaceuticals are on the edge of drug discovery. By integrating these computational and formulation-based strategies, researchers can enhance the rational design of BBB-permeable drugs while minimizing off-target effects. This review is valuable for understanding BBB selectivity principles and the latest in silico and nanotechnological approaches for improving CNS drug delivery.

1 November 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
HAHenrique de Oliveira Amaral
Henrique de Oliveira Amaral
VMVictoria Monge
Victoria Monge
AMAndréia Biolchi Mayer
Andréia Biolchi Mayer
GCGabriel Avohay Alves Campos
Gabriel Avohay Alves Campos
KLKamila Soares Lopes
Kamila Soares Lopes
Márcia MortariMárcia Mortari
Márcia Mortari

Verified
Journal Article
Open access
PDF file
SSSarah Schemmert
Sarah Schemmert
LCLuana Cristina Camargo
Luana Cristina Camargo
DHDominik Honold
Dominik Honold
IGIan Gering
Ian Gering
JKJanine Kutzsche
Janine Kutzsche
DWDieter Willbold
Dieter Willbold
Multiple sources of evidence suggest that soluble amyloid β (Aβ)-oligomers are responsible for the development and progression of Alzheimer’s disease (AD). In order to specifically eliminate these toxic Aβ-oligomers, our group has developed a variety of all-d-peptides over the past years. One of them, RD2, has been intensively studied and showed such convincing in vitro and in vivo properties that it is currently in clinical trials. In order to further optimize the compounds and to elucidate the characteristics of therapeutic d-peptides, several rational drug design approaches have been performed. Two of these d-peptides are the linear tandem (head-to-tail) d-peptide RD2D3 and its cyclized form cRD2D3. Tandemization and cyclization should result in an increased in vitro potency and increase pharmacokinetic properties, especially crossing the blood–brain-barrier. In comparison, cRD2D3 showed a superior pharmacokinetic profile to RD2D3. This fact suggests that higher efficacy can be achieved in vivo at equally administered concentrations. To prove this hypothesis, we first established the in vitro profile of both d-peptides here. Subsequently, we performed an intraperitoneal treatment study. This study failed to provide evidence that cRD2D3 is superior to RD2D3 in vivo as in some tests cRD2D3 failed to show equal or higher efficacy.

1 September 2017 in Peptides
Verified
Journal Article
Closed access
KLKamila Soares Lopes
Kamila Soares Lopes
GCGabriel Avohay Alves Campos
Gabriel Avohay Alves Campos
LCLuana Cristina Camargo
Luana Cristina Camargo
ASAdolfo Carlos Barros de Souza
Adolfo Carlos Barros de Souza
BIBeatriz Vasconcelos Ibituruna
Beatriz Vasconcelos Ibituruna
Márcia MortariMárcia Mortari
Márcia Mortari

3 July 2024 in ACS Chemical Neuroscience
Verified
Journal Article
Open access
LCLuana Cristina Camargo
Luana Cristina Camargo
IGIan Gering
Ian Gering
MMMohammadamin Mastalipour
Mohammadamin Mastalipour
VKVictoria Kraemer-Schulien
Victoria Kraemer-Schulien
TBTuyen Bujnicki
Tuyen Bujnicki
RERaphael Eberle
Raphael Eberle
Over a century has passed since Alois Alzheimer first described Alzheimer's disease (AD), and since then, researchers have made significant strides in understanding its pathology. One key feature of AD is the presence of amyloid-β (Aβ) peptides, which form amyloid plaques, and therefore, it is a primary target for treatment studies. Naturally occurring peptides have garnered attention for their potential pharmacological benefits, particularly in the central nervous system. In this study, nine peptide derivatives of Crotamine, a polypeptide from Crotalus durissus terrificus Rattlesnake venom, as well as one d-enantiomer, were evaluated for their ability to modulate Aβ42 aggregation through various assays such as ThT, QIAD, SPR, and sFIDA. All tested peptides were able to decrease Aβ42 aggregation and eliminate Aβ42 aggregates. Additionally, all of the peptides showed an affinity for Aβ42. This study is the first to describe the potential of crotamine derivative peptides against Aβ42 aggregation and to identify a promising d-peptide that could be used as an effective pharmacological tool against AD in the future.

Verified
Journal Article
Open access
PDF file
LCLuana Cristina Camargo
Luana Cristina Camargo
MSMichael Schöneck
Michael Schöneck
NSNivethini Sangarapillai
Nivethini Sangarapillai
DHDominik Honold
Dominik Honold
NSN. Jon Shah
N. Jon Shah
AWAntje Willuweit
Antje Willuweit
Understanding the physiopathology of Alzheimer’s disease (AD) has improved substantially based on studies of mouse models mimicking at least one aspect of the disease. Many transgenic lines have been established, leading to amyloidosis but lacking neurodegeneration. The aim of the current study was to generate a novel mouse model that develops neuritic plaques containing the aggressive pyroglutamate modified amyloid-β (pEAβ) species in the brain. The TAPS line was developed by intercrossing of the pEAβ-producing TBA2.1 mice with the plaque-developing line APPswe/PS1ΔE9. The phenotype of the new mouse line was characterized using immunostaining, and different cognitive and general behavioral tests. In comparison to the parental lines, TAPS animals developed an earlier onset of pathology and increased plaque load, including striatal pEAβ-positive neuritic plaques, and enhanced neuroinflammation. In addition to abnormalities in general behavior, locomotion, and exploratory behavior, TAPS mice displayed cognitive deficits in a variety of tests that were most pronounced in the fear conditioning paradigm and in spatial learning in comparison to the parental lines. In conclusion, the combination of a pEAβ- and a plaque-developing mouse model led to an accelerated amyloid pathology and cognitive decline in TAPS mice, qualifying this line as a novel amyloidosis model for future studies.